ArticleBMJ open respiratory research2025
Chronic obstructive pulmonary disease mortality rate trends in Taiwan, 2002-2022: a joinpoint regression analysis.
Article in BMJ open respiratory research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Air pollution, inhaled therapy and COPD exacerbations in Yunlin, Taiwan: a 2016-2024 single-centre retrospective cohort with environmental and carbon-footprint analyses.BMJ open respiratory research · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic respiratory diseases, particularly chronic obstructive pulmonary disease (COPD), are the eighth leading cause of death in Taiwan. Although COPD management has advanced in the previous two decades, mortality trends remain unclear. The present study analysed COPD mortality rates in Taiwan from 2002 to 2022.
methodsCOPD mortality and population data were obtained from Taiwan's National Health Statistics and the Ministry of the Interior's Demographic Yearbook. For comparison, global COPD mortality data were sourced from the WHO mortality database. A joinpoint analysis was conducted to assess trends in age-specific and age-standardised mortality rates across sex, region or country.
resultsFrom 2002 to 2022, Taiwan had 100 147 deaths attributed to COPD. The age-standardised mortality rate decreased with an annual average percentage change (AAPC) of -3.79%, which was more pronounced in women (AAPC: -4.28%) than in men (AAPC: -3.79%). The largest decline occurred from 2016 to 2022, with an AAPC of -7.70%. Most COPD-related deaths occurred among older individuals, with significant reductions in mortality rates observed among men aged ≥60 years and among women aged ≥50 years. A downward trend in COPD mortality rates was noted in most counties from 2016 to 2022, although patterns varied. The overall COPD mortality rate has declined in most countries since 2002, including Taiwan, which ranks third in Asia in terms of reductions in COPD mortality rates during this period.
conclusionFrom 2002 to 2022, COPD mortality rates in Taiwan declined considerably across sexes and regions, although patterns varied. In Asia, Taiwan's reduction in the rate of COPD mortality ranks third behind those of the Republic of Korea and Singapore. The reductions observed in COPD mortality rates in Taiwan may be attributable to tobacco control initiatives and nationwide COPD care programmes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.